Thomas Powles MBBS, MRCP, MD

Expert perspectives on optimal treatment approaches in patients with newly diagnosed metastatic urothelial carcinoma.

A brief overview of the advanced urothelial carcinoma landscape encompassing disease course and standard of care treatment strategies.

Thomas Powles, MBBS, MRCP, MD, discusses the rationale to evaluate circulating tumor DNA in high-risk muscle-invasive bladder cancer.

Thomas Powles, MBBS, MRCP, MD, discusses the role of circulating tumor DNA positivity in high-risk muscle-invasive urothelial cancer.

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the FDA approval of the combination of pembrolizumab (Keytruda) plus axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the results of the KEYNOTE-426 trial in metastatic renal cell carcinoma (mRCC).

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the rationale for the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses durvalumab in combination with a MET inhibitor in the treatment of patients with papillary renal cancer.

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses the current state of research in bladder cancer.

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses biomarkers for immunotherapy in bladder cancer.